LCI News and Press, Lannett Co Inc From 08/19/22

LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24 PR Newswire TREVOSE, Pa. , Aug. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financia...

Statistical surveys show April Recreational Vehicle or RV retail sales drop by 31%. Towables retail, that includes travel trailers, fifth wheels, camping trailers, and park models down 32% in April. Motorhomes retail fell 20% in April, Baird report estimates that April motorhome retail c...

LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE PR Newswire Approximately Half of the Planned Number of Subjects Have Received the First Dose, With No Reported Serious Adverse Events Study Progressing On Schedule ...

Lannett (NYSE:LCI) signed an agreement with Areva Pharmaceuticals to be the exclusive U.S. distributor of Fludarabine Phosphate for injection, a generic version of Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) Fludara to treat  chronic lymphocytic leukemia. Trevose, Pa.-based L...

LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP PR Newswire -- Current Drug Market Shortage Exists for Fludarabine Phosphate, An Injectable Chemotherapeutic Medication; Marketing Anticipated to Commence Later This ...

Lannett Company, Inc. (LCI) Q3 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations, Robert Jaffe Co., LLC Timothy Crew - Chief Executive Officer John Kozlowski - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Cap...

LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS PR Newswire Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31 Completed Sale of Liquid Manufacturing Plant for ...

LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4 PR Newswire TREVOSE, Pa. , April 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for i...

Lannett (NYSE:LCI) said it began a pivotal clinical trial of biosimilar insulin glargine, Sanofi's (SNY) Lantus. The company is co-developing the product with its strategic alliance partners within the HEC Group of companies (HEC). Lannett said a prior first study, which the FDA rev...

LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE PR Newswire --First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024-- TREVOSE, Pa. ...